Associated tags: Health technology, DSM-IV codes, HSDT, Pons, Patient, Helios, Gait, MS, Multiple sclerosis, Pharmaceutical industry, Tongue, Sale
Locations: CANADA, NEW YORK, SOUTH CAROLINA, PT, WALL STREET, CA, BROOKS, NEWTOWN, PA, US, MS, LOVELL, VA, UNITED STATES, TN
Retrieved on:
Thursday, September 29, 2022
Gait,
Multiple sclerosis,
Traumatic brain injury,
Sale,
Neurology,
Roth Capital Partners,
Lists of diseases,
MS,
Patient,
Pons,
Helios,
TEP,
Tongue,
Medical device Investors and attendees who would like to schedule a 1-on-1 meeting with Helius management are asked to contact their Roth Capital representative to arrange a meeting.
Key Points:
- Investors and attendees who would like to schedule a 1-on-1 meeting with Helius management are asked to contact their Roth Capital representative to arrange a meeting.
- Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brains ability to compensate and promote neuroplasticity, improving the lives of people dealing with neurologic diseases.
- The Companys first commercial product is the Portable Neuromodulation Stimulator (PoNS).
- PoNS is also authorized for sale in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait.
Retrieved on:
Wednesday, September 14, 2022
Gait,
Employment,
Multiple sclerosis,
Traumatic brain injury,
Acceleration,
Sale,
Neurology,
Company,
Lists of diseases,
Patient,
MS,
Pons,
Helios,
Nasdaq,
HSDT,
TEP,
GLOBE,
Tongue NEWTOWN, Pa., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT ) (Helius or the Company), a neurotech company focused on neurological wellness, today announced that, effectiveSeptember 13, 2022, its compensation committee approved an equity award under Helius 2021 Inducement Plan, as a material inducement to an individual entering into employment with the Company.
Key Points:
- NEWTOWN, Pa., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT ) (Helius or the Company), a neurotech company focused on neurological wellness, today announced that, effectiveSeptember 13, 2022, its compensation committee approved an equity award under Helius 2021 Inducement Plan, as a material inducement to an individual entering into employment with the Company.
- The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.
- The option award has an exercise price of$0.54per share, the closing price of Helius common stock onSeptember 13, 2022, the date of the grant.
- Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brains ability to compensate and promote neuroplasticity, improving the lives of people dealing with neurologic diseases.
Retrieved on:
Tuesday, September 6, 2022
Lists of diseases,
Helios,
Multiple sclerosis,
Sale,
Gait,
Tongue,
Neurology,
TEP,
Traumatic brain injury,
MS,
Pons,
Health technology,
Patient,
Medical device Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brains ability to compensate and promotes neuroplasticity, aiming to improve the lives of people dealing with neurologic diseases.
Key Points:
- Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brains ability to compensate and promotes neuroplasticity, aiming to improve the lives of people dealing with neurologic diseases.
- The Companys first commercial product is the Portable Neuromodulation Stimulator (PoNS).
- The Portable Neuromodulation Stimulator (PoNS) is an innovative non-surgical medical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the surface of the tongue to improve balance and gait.
- PoNS is also authorized for sale in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait.
U.S. Securities and Exchange Commission,
Forward-looking statement,
Medicare,
MS,
Newsroom,
Growth,
Sale,
Prospectus,
TEP,
Pons,
Patient,
COVID-19,
Company,
Contract,
Neurology,
Therapy,
Gait,
Lists of diseases,
News,
Webcast,
Private Securities Litigation Reform Act,
Helios,
Internet,
Multiple sclerosis,
Tongue,
Regulation,
Traumatic brain injury,
Public relations,
Pharmaceutical industry,
Medicaid NEWTOWN, Pa., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported financial results for the quarter ended June 30, 2022.
Key Points:
- * Beginning this quarter, conference call participants should register to obtain their dial-in and passcode details.
- Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brains ability to compensate and promotes neuroplasticity, aiming to improve the lives of people dealing with neurologic diseases.
- All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties.
- Forward-looking statements are often identified by terms such as believe, continue, expect, will, goal, aim to and similar expressions.
Retrieved on:
Wednesday, August 10, 2022
MS,
Newsroom,
Sale,
TEP,
Pons,
Patient,
Company,
Neurology,
Gait,
Lists of diseases,
PTAP,
Webcast,
Helios,
Multiple sclerosis,
Tongue,
Traumatic brain injury,
Medical device * Beginning this quarter, conference call participants should register to obtain their dial-in and passcode details.
Key Points:
- * Beginning this quarter, conference call participants should register to obtain their dial-in and passcode details.
- The new, streamlined process improves security and eliminates wait times when joining the call.
- The Company has also initiated its Patient Therapy Access Program (PTAP), which provides qualifying patients access to on-label PoNS Therapy at a significantly reduced price.
- PoNS is also authorized for sale in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait.
HSDT,
U.S. Securities and Exchange Commission,
SEC filing,
Industry,
Forward-looking statement,
GLOBE,
Form,
Suite,
Roth Capital Partners,
Sale,
Prospectus,
LLC,
Security (finance),
Company,
News,
Private Securities Litigation Reform Act,
Nasdaq The offering is expected to close on or about August 9, 2022, subject to customary closing conditions.
Key Points:
- The offering is expected to close on or about August 9, 2022, subject to customary closing conditions.
- Roth Capital Partners, LLC is acting as lead placement agent and Maxim Group LLC is acting as co-placement agent of the offering.
- Gross proceeds, before deducting placement agent fees and commissions and offering expenses are expected to be $18 million.
- Such forward-looking statements include, among others, statements regarding the Companys anticipated closing of the public offering and anticipated use of proceeds therefrom.
Online,
Internet,
Compte rendu,
Pons,
Sale,
Tongue,
Neurology,
TEP,
Therapy,
News,
HSDT,
Company,
Regulation,
Multiple sclerosis,
Patient,
Lists of diseases,
GLOBE,
COVID-19,
Private Securities Litigation Reform Act,
PTAP,
Gait,
Time,
Medicare,
Nasdaq,
Forward-looking statement,
MS,
FDA,
Curriculum,
Software,
Traumatic brain injury,
Specialization,
U.S. Securities and Exchange Commission,
Contract,
Pharmaceutical industry,
Medicine,
Medicaid,
Helios We are pleased to introduce our online PoNS Therapy training curriculum.
Key Points:
- We are pleased to introduce our online PoNS Therapy training curriculum.
- In the past, physical therapists treating gait deficit in patients with MS received PoNS training through an in-person, multi-day course.
- Our new online module allows training to be completed in three hours, or less, at the therapists own pace.
- PoNS Therapy training modules are now live for registrants to complete at their own pace.
Research,
Pons,
Doctor of Philosophy,
Week,
Labe,
HSDT,
Annual general meeting,
Nasdaq,
GLOBE,
Patient,
MS,
Rehabilitation,
Data,
Poster,
MD,
FGA,
Pharmaceutical industry,
Helios NEWTOWN, Pa., June 06, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that a poster detailing the benefits of the Company’s Portable Neuromodulation Stimulator (“PoNS”) Therapy combined with a therapeutic exercise program was presented at the 2022 Consortium of Multiple Sclerosis Centers (“CMSC”) Annual Meeting held June 1-4, 2022, in National Harbor, Maryland.
Key Points:
- The CMSC Annual Meeting is a wonderful opportunity to engage with thought leaders and researchers in the MS space.
- It is especially gratifying that our poster was selected out of 150 to receive a prestigious award nomination, stated Antonella Favit-VanPelt, MD, PhD, Chief Medical Officer of Helius.
- Importantly, this latest dataset provides key real-world evidence of our therapys clinical benefits, which can be seen at two weeks from beginning rehabilitation treatment with PoNS.
- Mean improvements in FGA total scores based on observed data were highly statistically significant at all follow-up time points (paired t-test P
Company,
Program,
TEP,
Pons,
Lists of diseases,
Contract,
Forward-looking statement,
Medicare,
HSDT,
Letter,
PTAP,
Tongue,
News,
Nasdaq,
Regulation,
Traumatic brain injury,
Therapy,
Sale,
FDA,
GLOBE,
Patient,
MS,
Private Securities Litigation Reform Act,
COVID-19,
Gait,
Adoption,
Management of multiple sclerosis,
Internet,
CMS,
Multiple sclerosis,
Neurology,
U.S. Securities and Exchange Commission,
Pharmaceutical industry,
Helios,
Medicaid NEWTOWN, Pa., June 01, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (Helius or the Company), a neurotech company focused on neurological wellness, today announced the launch of its Patient Therapy Access Program (PTAP), which will provide qualifying patients access to on-label Portable Neuromodulation Stimulator (PoNS) Therapy at a significantly reduced price.
Key Points:
- NEWTOWN, Pa., June 01, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (Helius or the Company), a neurotech company focused on neurological wellness, today announced the launch of its Patient Therapy Access Program (PTAP), which will provide qualifying patients access to on-label Portable Neuromodulation Stimulator (PoNS) Therapy at a significantly reduced price.
- Our goal is to bring treatment to as many qualifying patients as possible and we are proud to introduce our Patient Therapy Access Program for potential first-time users, stated Dane Andreeff, President and Chief Executive Officer of Helius.
- With the proper prescription and a letter of medical necessity, people struggling with MS in the U.S. will be able to access PoNS Therapy at a greatly reduced price.
- We believe this program will accelerate the adoption of PoNS Therapy and help to establish PoNS as the standard of care for MS patients with gait deficit.
Pons,
Annual general meeting,
Lists of diseases,
Consortium,
Tongue,
National Harbor, Maryland,
Nasdaq,
Doctor of Philosophy,
Patient,
National Primate Research Exhibition Hall,
Neuroplasticity,
HSDT,
Convention,
CMSC,
Booth,
MS,
Multiple sclerosis,
Gait,
MD,
GLOBE,
Medical device We are excited to share our real-world findings on neuromodulation to improve MS patients ability to walk steadily and safely, said Antonella Favit-Van Pelt, MD, PhD, Helius Medicals Chief Medical Officer.
Key Points:
- We are excited to share our real-world findings on neuromodulation to improve MS patients ability to walk steadily and safely, said Antonella Favit-Van Pelt, MD, PhD, Helius Medicals Chief Medical Officer.
- Our findings show that neuromodulation stimulation is an effective rehabilitative intervention that is thought to engage mechanisms of upregulation and long-term potentiation, promoting neuroplasticity and improving gait functionality and mobility.
- Helius Medical representatives will be available to talk about how neuromodulation can help improve gait for individuals with MS at Booth #804 in the Exhibit Hall.
- Helius Medical is manufacturer of the Portable Neuromodulation Stimulator (PoNS), an innovative non-surgical medical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the surface of the tongue to improve balance and gait.
